All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
On 8 August 2018, the US Food and Drug Administration approved the use of mogamulizumab-kpkc (POTELIGEO) for adult patients with relapsed or refractory (R/R) mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior line of therapy.
Mogamulizumab-kpkc is a CC chemokine receptor type 4 directed monoclonal antibody used to treat MF or SS, which is a type of cutaneous T-cell lymphoma (CTCL). The approval follows data from a randomized, multi-center, phase III trial (NCT01728805) that compared patients with R/R MF or SS treated with either mogamulizumab-kpkc or vorinostat. Progression-free survival (PFS) was significantly superior in the mogamulizumab-kpkc treatment arm compared with vorinostat. The PFS for mogamulizumab-kpkc was 7.6 months (95% CI, 5.6, 10.2) and the PFS for vorinostat was 3.1 months (95% CI, 2.8, 4.0), (HR 0.53, 95% CI, 0.41, 0.69), P < 0.001. The overall response rate (ORR) for mogamulizumab-kpkc was 28% compared with 5% for vorinostat, P < 0.001.
The MAVORIC phase III trial: vorinostat versus mogamulizumab for previously treated CTCL
In patients with previously-treated mycosis fungoides or Sézary syndrome, mogamulizumab led to significantly superior PFS and ORR than vorinostat.
ASH 2016 | Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
Oral abstract #181 at ASH 2016 was presented by Michael Khodadoust, MD, PhD, and included...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox